Cleveland BioLabs [CBLI] has received a potential $8.9 million contract from the Defense Department's Chemical Biological Medical Systems (CBMS) Joint Program Management Office for the advanced development of Protectan CBLB502 as a medical radiation countermeasure to treat radiation injury following exposure to radiation from nuclear or radiological weapons. Earlier this year Osiris Therapeutics [OSIR] won a potential $225 million contract from DoD to develop its Prochymal adult stem therapy for the repair of gastrointestinal injury due to radiation exposure (TR2,…
DoD Awards Cleveland BioLabs $9M for Medical Rad Countermeasures
SHARE: